Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M124Revenue (TTM) $M--Net Margin (%)--Altman Z-Score-0.1
Enterprise Value $M52.4EPS (TTM) $-3.5Operating Margin %--Piotroski F-Score2
P/E(ttm)--Beneish M-Score-3.7Pre-tax Margin (%)--Higher ROA y-yN
Price/Book1.510-y EBITDA Growth Rate %--Quick Ratio9.9Cash flow > EarningsY
Price/Sales--5-y EBITDA Growth Rate %-4.5Current Ratio9.9Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-58.7Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-68.8Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M22.6ROIC % (ttm)-258.9Gross Margin Increase y-yN

Gurus Latest Trades with CASC

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CASCSeth Klarman 2016-06-30 Buy 0.32%$5.1 - $8.1
($6.8)
$ 5.50-19%New holding4,166,675
CASCFirst Eagle Investment 2016-06-30 Buy $5.1 - $8.1
($6.8)
$ 5.50-19%New holding66,667
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CASC is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


CASC: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Myers Scott DunsethPresident and CEO 2016-08-17Buy7,500$6.9-20.29view
Myers Scott DunsethPresident and CEO 2016-06-28Buy10,417$4.814.58view
HAUSMAN DIANAChief Medical Officer 2015-06-01Buy5,747$4.6518.28view
SPIEGELMAN DANIEL KDirector 2015-03-26Buy20,000$1.61241.61view
SPIEGELMAN DANIEL KDirector 2015-03-26Buy20,000$1.61241.61view
BVF PARTNERS L P/IL10% Owner 2014-12-12Sell0$0241.61view
Venkatesan JayEVP and General Manager 2014-09-23Buy250,000$2175view
BVF PARTNERS L P/IL10% Owner 2013-11-01Buy129,000$1.78208.99view
BVF PARTNERS L P/IL10% Owner 2013-08-08Buy258,361$1.65233.33view
BVF PARTNERS L P/IL10% Owner 2013-08-01Buy338,087$1.74216.09view

Quarterly/Annual Reports about CASC:

    News about CASC:

    Articles On GuruFocus.com
    Seth Klarman Buys 25 Million Shares of Cascadian Therapeutics as Price Declines Jul 12 2016 
    Seth Klarman Buys 25 Million Shares of Cascadian Therapeutics Jul 11 2016 
    Value Betting with Special Situations: Lessons from the World of Gambling Mar 05 2013 
    Cubist Pharmaceutical - Acutely Aware May 09 2010 

    More From Other Websites
    Cascadian Therapeutics, Inc. :CASC-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016 Dec 01 2016
    Cascadian Therapeutics Strengthens Management Team with Key Hires, Monique M. Greer and Marc C.... Nov 28 2016
    Cascadian Therapeutics Announces Stockholders and Board of Directors Approve Reverse Stock Split Nov 23 2016
    CASCADIAN THERAPEUTICS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in... Nov 23 2016
    Cascadian Therapeutics Announces Stockholders and Board of Directors Approve Reverse Stock Split Nov 23 2016
    CASCADIAN THERAPEUTICS, INC. Financials Nov 16 2016
    Cascadian Therapeutics Announces Presentations of Updated Clinical Data at the 2016 San Antonio... Nov 15 2016
    CASCADIAN THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 07 2016
    Cascadian Therapeutics reports 3Q loss Nov 07 2016
    Cascadian Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update Nov 07 2016
    Cascadian Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update Nov 07 2016
    Cascadian Therapeutics Announces Presentation of Tucatinib in Combination Therapy in Patients with... Oct 10 2016
    Cascadian Therapeutics Announces Presentation of Tucatinib in Combination Therapy in Patients with... Oct 10 2016
    Cascadian Therapeutics (CASC) Shares March Higher, Can It Continue? Oct 06 2016
    CASCADIAN THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 04 2016
    Cascadian Therapeutics Announces Proposal for Reverse Stock Split Oct 04 2016
    Cascadian Therapeutics Announces Proposal for Reverse Stock Split Oct 04 2016
    Cascadian Therapeutics Announces Poster Presentations on Tucatinib at the European Society of... Sep 28 2016
    Cascadian Therapeutics to Present at the Ladenburg Thalmann 2016 Healthcare Conference Sep 20 2016
    Cascadian Therapeutics, Inc. :CASC-US: Earnings Analysis: Q2, 2016 By the Numbers : September 16,... Sep 16 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)